About: Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice
Creator	Lee, Tae-Young Kim, Jeong-Ki Sung, Moon-Hee Poo, Haryoung Kim, Yang-Hyun Lee, Il-Han Lee, Kyung-Soon Park, Jong-Sup Yang, Jai-Myung
Source	Medline; PMC
abstract	Given that local cell-mediated immunity (CMI) against the human papillomavirus type 16 E6 (HPV16 E6) protein is important for eradication of HPV16 E6-expressing cancer cells in the cervical mucosa, the HPV16 E6 protein may be a target for the mucosal immunotherapy of cervical cancer. Here, we expressed the HPV16 E6 antigen on Lactobacillus casei (L. casei) and investigated E6-specific CMI following oral administration of the L. casei-PgsA-E6 to mice. Surface expression of HPV16 E6 antigens was confirmed and mice were orally inoculated with the L. casei-PgsA or the L. casei-PgsA-E6. Compared to the L. casei-PgsA-treated mice, significantly higher levels of serum IgG and mucosal IgA were observed in L. casei-PgsA-E6-immunized mice; these differences were significantly enhanced after boost. Consistent with this, systemic and local CMI were significantly increased after the boost, as shown by increased counts of IFN-γ-secreting cells in splenocytes, mesenteric lymph nodes (MLN), and vaginal samples. Furthermore, in the TC-1 tumor model, animals receiving the orally administered L. casei-PgsA-E6 showed reduced tumor size and increased survival rate versus mice receiving control (L. casei-PgsA) immunization. We also found that L. casei-PgsA-E6-induced antitumor effect was decreased by in vivo depletion of CD4(+) or CD8(+) T cells. Collectively, these results indicate that the oral administration of lactobacilli bearing the surface-displayed E6 protein induces T cell-mediated cellular immunity and antitumor effects in mice.
has issue date	2010-08-13(xsd:dateTime)
bibo:doi	10.1007/s00262-010-0903-4
bibo:pmid	20706715
has license	no-cc
sha1sum (hex)	dcd41f49e07917307a078489eb212c4b1c3a201b
schema:url	https://doi.org/10.1007/s00262-010-0903-4
resource representing a document's title	Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice
has PubMed Central identifier	PMC7079958
has PubMed identifier	20706715
schema:publication	Cancer Immunol Immunother
resource representing a document's body	covid:dcd41f49e07917307a078489eb212c4b1c3a201b#body_text
is schema:about of	named entity 'induced' named entity 'L. casei' named entity 'TC-1' named entity 'boost' named entity 'mice' named entity 'ANTITUMOR' named entity 'FOUND' named entity 'DECREASED BY' named entity 'MAY BE A' named entity 'COMPARED' named entity 'MEDIATED' named entity 'IMMUNIZATION' named entity 'SURVIVAL RATE' named entity 'ADMINISTERED' named entity 'MICE' named entity 'ERADICATION' named entity 'THESE' named entity 'DISPLAYED' named entity 'CD8' named entity 'ANIMALS' named entity 'MUCOSAL' named entity 'IFN' named entity 'LACTOBACILLUS CASEI' named entity 'HUMAN PAPILLOMAVIRUS TYPE 16' named entity 'CELLS' named entity 'VAGINAL' named entity 'SYSTEMIC' named entity 'REDUCED' named entity 'MICE' covid:arg/dcd41f49e07917307a078489eb212c4b1c3a201b named entity 'INDUCED' named entity 'HPV16 E6' named entity 'ORAL ADMINISTRATION' named entity 'COUNTS' named entity 'RESULTS' named entity 'HIGHER' named entity 'IMMUNITY' named entity 'C57BL' named entity 'T CELL' named entity 'SPECIFIC' named entity 'CONTROL' named entity 'SAMPLES' named entity 'E6 PROTEIN' named entity 'GIVEN' named entity 'LEVELS' named entity 'CONSISTENT WITH' named entity 'MESENTERIC LYMPH NODES' named entity 'IGG' named entity 'INVESTIGATED' named entity 'ANTIGENS' named entity 'TC-1' named entity 'IMPORTANT' named entity 'T CELLS' named entity 'INDUCED' named entity 'CONFIRMED' named entity 'SERUM' named entity 'HPV16 E6' named entity 'CANCER CELLS' named entity 'ANTIGEN' named entity 'EXPRESSED' named entity 'OBSERVED' named entity 'RECEIVING' named entity 'DEPLETION' named entity 'PGSA' named entity 'ENHANCED' named entity 'LOCAL' named entity 'TUMOR SIZE' named entity 'HUMAN PAPILLOMAVIRUS TYPE 16' named entity 'CELL-MEDIATED IMMUNITY' named entity 'ANTITUMOR' named entity 'EFFECT' named entity 'HERE' named entity 'CERVICAL MUCOSA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software